

## After a successful test period, ZymIQ signs agreement in Malaysia

**ZymIQ Technology AB has signed another exclusive distribution agreement for its animal health products in Asia. The agreement has been signed with KM VET PHARM Sdn Bhd. and covers Malaysia.**

Earlier this year, ZymIQ began the internationalization of its animal health products outside Sweden. The focus on selected markets in Asia is progressing according to plan, and a distribution agreement for Thailand has already been signed. Now, another step has been taken in this process with an exclusive distribution agreement for Malaysia with KM VET PHARM Sdn Bhd, Kuala Lumpur.

The agreement with KM VET PHARM covers all animal health products in the Kalzyme™ product line. The agreement process followed a trial period of about two years, during which KM VET PHARM evaluated the products together with leading veterinarians within the group. The results were highly successful, with strong repeat purchase rates among customers.

KM VET PHARM is one of Malaysia's largest veterinary pharmacies and animal health suppliers, and is part of a group that also includes its own animal hospital. KM VET PHARM is a family-owned company, founded in 1991, with a focus on domestic sales in a country where a large share of the 35 million inhabitants own a dog or cat.

Kalzyme™, already an established brand in the Swedish market, is a series of enzyme-based dental and dermal products with clinically proven effects. Developed by researchers and veterinarians, the products are designed to offer safe and effective health solutions that promote the well-being of dogs and cats.

"The interest in our unique Kalzyme products is very strong, even far beyond the Nordic region. It takes some time to complete evaluations in new markets, but it's important to get it right. We are excited to follow our entry into some of Asia's largest markets" says Michael Edelborg Christensen, CEO of ZymIQ.

\* Every care has been taken in the translation of this Press release. In the event of discrepancies, the Swedish original will supersede the English translation.

**For more information, please contact:**

Michael Edelborg Christensen, CEO

Phone +46 727 144 166

Email: [michael.christensen@zymiq.com](mailto:michael.christensen@zymiq.com)

**About ZymIQ**

ZymIQ Technology AB (publ) is a life science company headquartered in Lund, Sweden and the parent company of the ZymIQ Group. Subsidiaries include ZymIQ Biopharma AB, Sweden and ZymIQ Animal Health LLC, Virginia, USA. The company is also represented by offices in Singapore and Malaysia. ZymIQ develops, manufactures and sells innovative enzyme-based therapeutic and cosmetic products for the well-being of humans and animals. ZymIQ also conducts pioneering research on future alternatives to antibiotics to combat the global challenge of antibiotic resistance, [www.zymiq.com](http://www.zymiq.com)

**Attachments**

[After a successful test period, ZymIQ signs agreement in Malaysia](#)